Patents by Inventor Cagan Gurer

Cagan Gurer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-human animals having a humanized B-cell activating factor gene
    Patent number: 9629347
    Abstract: Non-human animals, cells, methods and compositions for making and using the same are provided, wherein the non-human animals and cells comprise a humanized B-cell activating factor gene. Non-human animals and cells that express a human or humanized B-cell activating factor protein from an endogenous B-cell activating factor locus are described.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: April 25, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: John McWhirter, Cagan Gurer, Lynn Macdonald, Andrew J. Murphy
  • Human Lambda Light Chain Mice
    Publication number: 20170107484
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Application
    Filed: January 4, 2017
    Publication date: April 20, 2017
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Humanized light chain mice
    Patent number: 9622459
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: April 18, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Sean Stevens, Andrew J. Murphy
  • Genetically modified major histocompatibility complex mice
    Patent number: 9615550
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: April 11, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens
  • HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING VL DOMAINS
    Publication number: 20170094955
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a rodent (e.g., a mouse), wherein the non-human animals rearrange human immunoglobulin light chain gene segments in the context of heavy chain constant regions and express immunoglobulin-like molecules comprising human immunoglobulin light chain variable domains fused to heavy chain constant domains that are cognate with human immunoglobulin light chain variable domains fused to light chain constant domains.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 6, 2017
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Sean Stevens, Andrew J. Murphy
  • Non-Human Animals Having Humanized FC-Gamma Receptors
    Publication number: 20170086432
    Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.
    Type: Application
    Filed: September 27, 2016
    Publication date: March 30, 2017
    Inventors: Andrew J. Murphy, Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Naxin Tu
  • Genetically modified major histocompatibility complex animals
    Patent number: 9591835
    Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I polypeptide and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: March 14, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Andrew J. Murphy, Cagan Gurer, John McWhirter, Vera Voronina, Faith Harris, Sean Stevens, Yingzi Xue
  • Genetically modified major histocompatibility complex mice
    Patent number: 9585373
    Abstract: The invention provides genetically modified non-human animals that express a humanized MHC II protein (humanized MHC II ? and ? polypeptides), as well as embryos, cells, and tissues comprising the humanized MHC II protein. Also provided are constructs for and methods of making the genetically modified non-human animals. Methods of using the genetically modified non-human animals to study various aspects of the human immune system are provided.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 7, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Andrew J Murphy, Naxin Tu, Cagan Gurer, Vera Voronina, Sean Stevens
  • Human lambda light chain mice
    Patent number: 9540452
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: January 10, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • NON-HUMAN ANIMALS HAVING A HUMANIZED SIGNAL-REGULATORY PROTEIN GENE
    Publication number: 20160374321
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Application
    Filed: September 13, 2016
    Publication date: December 29, 2016
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • Mice that make VL binding proteins
    Patent number: 9516868
    Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: December 13, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE
    Publication number: 20160345549
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: November 25, 2015
    Publication date: December 1, 2016
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Non-human animals having humanized Fc-gamma receptors
    Patent number: 9474255
    Abstract: Genetically modified mice and methods and compositions for making and using the same are provided, wherein the genetic modification comprises humanization of an Fc?RI protein.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: October 25, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Lynn Macdonald, Cagan Gurer, Karolina A. Meagher, Naxin Tu
  • GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF
    Publication number: 20160295844
    Abstract: Genetically modified non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome are provided. Also provided are methods for making non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome, and methods for using non-human animals expressing human SIRP? and human IL-15 from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modeling human T cell and/or natural killer (NK) cell development and function, in modeling human pathogen infection of human T cells and/or NK cells, and in various in vivo screens.
    Type: Application
    Filed: April 12, 2016
    Publication date: October 13, 2016
    Inventors: Dietmar Herndler-Brandstetter, Richard A. Flavell, Davor Frleta, Cagan Gurer, Markus Gabriel Manz, Andrew J. Murphy, Noah W. Palm, Liang Shan, Sean Stevens, Till Strowig, George D. Yancopoulos, Marcel de Zoete
  • Non-human animals having a humanized signal-regulatory protein gene
    Patent number: 9462794
    Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP? gene. Genetically modified mice are described, including mice that express a human or humanized SIRP? protein from an endogenous SIRP? locus.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 11, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Andrew J. Murphy, O. Gavin Thurston, Bindu Varghese, Cagan Gurer
  • Human lambda light chain mice
    Patent number: 9399683
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: July 26, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Human lambda light chain mice
    Patent number: 9394373
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: July 19, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE
    Publication number: 20160157470
    Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an endogenous cluster of differentiation (CD) gene, in particular a humanization of a CD47 gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD47 gene so that said non-human animals express a CD47 polypeptide that includes a human portion and a non-human portion (e.g., a murine portion).
    Type: Application
    Filed: January 19, 2016
    Publication date: June 9, 2016
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Cagan Gurer, Ella Ioffe, Alexander Mujica, Gavin Thurston
  • Hybrid light chain mice
    Patent number: 9334333
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: May 10, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • NON-HUMAN ANIMALS WITH MODIFIED IMMUNOGLOBULIN HEAVY CHAIN SEQUENCES
    Publication number: 20160100561
    Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.
    Type: Application
    Filed: December 7, 2015
    Publication date: April 14, 2016
    Inventors: John McWhirter, Cagan Gurer, Karolina A. Meagher, Lynn Macdonald, Andrew J. Murphy